Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible ...

In this GEN webinar, LV expert Brianna Jayanthi, PhD, will discuss how Asimov's LV Edge Producer and Packaging Systems are leading to higher-quality, higher-productivity cell lines to support clinical ...

Rocket Pharmaceuticals advances gene therapies for rare diseases. Momentum aligns with broader biotech trends in the Nasdaq ...

Contract development and manufacturing organization (CDMO) Matica Biotechnology has partnered with Calidi Biotherapeutics to advance and manufacture CLD-401, a tumor-tropic oncolytic virus designed to ...

Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific ...

India has achieved a major milestone in medical science with NexCAR19, the world’s first humanised CAR-T (Chimeric Antigen Receptor T-cell) therapy, which has made gene-based cancer treatments both ...

Prime Minister Narendra Modi gifted three path-breaking innovations, including CART-T Cell Therapy, India''s first indigemous cancer cell therapy developed by Indian Innovators with the support of the ...

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

The same lot of the lentiviral vector was used at both sites. The patients received nonmyeloablative conditioning with busulfan before the infusion of gene-corrected cells. Therapeutic drug monitoring ...

India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in ...

Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...